Tag: HIV prevention
-
England and Wales Set to Welcome HIV-Prevention Jab CAB-LA as Game-Changing PrEP Option
Overview: A new chapter in HIV prevention A potential breakthrough in the fight against HIV is on the cusp of becoming standard care in England and Wales. Cabotegravir, known as CAB-LA, is an injectable pre-exposure prophylaxis (PrEP) option that could be administered every two months to reduce the risk of HIV infection among HIV-negative adults…
-
New HIV Prevention Jab Set to Transform PrEP in England and Wales
Overview: A New Chapter in HIV Prevention A long-awaited option for preventing HIV infection is moving closer to routine use in England and Wales. Cabotegravir (CAB-LA), a long-acting injectable that is administered every two months, is poised to become the first injectable form of PrEP (pre-exposure prophylaxis) approved by the National Institute for Health and…
-
England and Wales poised to approve game-changing HIV prevention jab
New injectable PrEP set to reshape HIV prevention England and Wales are nearing a landmark decision that could alter the landscape of HIV prevention. A long-acting injectable drug, cabotegravir (CAB-LA), is recommended for use in adults and young people who are HIV-negative, with the aim of reducing new infections. Unlike the routine daily tablets used…
-
Determinants of mpox Vaccination Uptake Among MSM During the 2022 Outbreak: Insights from a Lyon Hospital Study
Background and Objectives The 2022 mpox outbreak prompted targeted vaccination for at‑risk groups, notably men who have sex with men (MSM) with multiple partners. Aiming to quantify first-dose uptake and understand its drivers, researchers conducted a single‑centre retrospective analysis at the STI and HIV clinics of Lyon University Hospital, France. The study focused on three…
-
Why Do Young Filipinos Continue to Test Positive for HIV?
Rising HIV Rates in the Philippines: A Complex Landscape The Philippines has witnessed a dramatic surge in HIV cases over the past decade, despite regional declines elsewhere in Asia. Between 2010 and 2024, the country reported a roughly 550% increase in new infections, prompting renewed calls to treat HIV as a public health emergency. The…
-
Fiji’s HIV Surge: Bluetoothing, Chemsex and Needle Sharing Drive a National Crisis
Overview: a rapidly escalating HIV situation in Fiji In recent years, Fiji has witnessed one of the world’s fastest-growing HIV epidemics. From a few hundred people living with HIV in 2014 to roughly 5,900 by 2024, the island nation now confronts a public health emergency that has alarmed doctors, policymakers, and advocates alike. The surge…
-
PrEP in Brazil: Daily vs On-Demand and Digital Adherence Needs
Introduction New qualitative insights from Brazil illuminate how cisgender men perceive daily versus on-demand HIV pre-exposure prophylaxis (PrEP), and what they want from digital tools to support adherence. The study, conducted across five Brazilian cities, interviewed 19 individuals and held five focus groups with 47 participants. It reveals a nuanced landscape where regimen choice, daily…
-
Perceptions of Daily and On-Demand PrEP and Digital Adherence Needs Among Cisgender Men in Brazil
Understanding PrEP in Brazil: Daily vs. On‑Demand and the Promise of Digital Support Oral HIV pre-exposure prophylaxis (PrEP) shields sexually active individuals from HIV infection using two antiretroviral drugs. In Brazil, as in many places, PrEP is most commonly taken daily, while an event‑driven or on‑demand regimen (2+1+1 dosing) offers an alternative for those with…
-
Perceptions of Daily and On-Demand HIV PrEP and Digital Adherence Needs Among Cisgender Men in Brazil: Qualitative Interview and Focus Group Study
Understanding PrEP in Brazil: Daily vs. On‑Demand and the Role of Digital Support Oral HIV pre-exposure prophylaxis (PrEP) is a cornerstone of modern prevention, with daily regimens and event-driven, or on‑demand, dosing options. A qualitative study across five Brazilian cities explored how cisgender men perceive these regimens, what drives their choices, and how a smartphone…
-
Lenacapavir: HIV prevention price slashed for LMICs
What is Lenacapavir and why does it matter for HIV prevention? Lenacapavir, marketed under the brand name Yeytuo, is a long-acting HIV prevention treatment that is injected twice a year. The EU approval placed it among the few options designed to simplify and strengthen pre- exposure prophylaxis (PrEP) by reducing the burden of daily pills.…